Literature DB >> 25931951

Unresectable pancreatic adenocarcinoma with complete clinical response following chemoradiotherapy.

Erol Aksoy1, Murat Ulaş1, Muhammet Kadri Çolakoğlu1, İlter Özer1, Erdal Birol Bostancı1, Musa Akoğlu1.   

Abstract

Locally advanced or metastatic disease is present in 2/3s of patients with pancreatic cancer. Pancreatic cancer patients are assessed as resectable, potentially resectable (borderline) and unresectable according to pre-operative examinations. The chance for operability may be enhanced by using adjuvant-neoadjuvant systemic chemotherapy, radiotherapy or both. The rates of R0 resection may be increased by means of treatment delivered this way. This case report presents a pancreatic adenocarcinoma case that was assessed to be resectable but was identified to be unresectable during surgical exploration, thus received adjuvant chemoradiotherapy. The patient was then re-evaluated, identified as resectable and received pancreaticoduodenectomy.

Entities:  

Keywords:  Pancreas; adenocarcinoma; chemotherapy; resectability

Year:  2015        PMID: 25931951      PMCID: PMC4415551          DOI: 10.5152/UCD.2014.2210

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  9 in total

1.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

2.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

Authors:  Timothy R Donahue; William H Isacoff; O Joe Hines; James S Tomlinson; James J Farrell; Yasser M Bhat; Edward Garon; Barbara Clerkin; Howard A Reber
Journal:  Arch Surg       Date:  2011-07

3.  A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.

Authors:  Higinia R Cardenes; Annette M Moore; Cynthia S Johnson; Menggang Yu; Paul Helft; Elena G Chiorean; Jacob Vinson; Thomas J Howard; Anthony W Stephens; D Fritz Tai; Patrick J Loehrer
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

4.  Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study.

Authors:  J P Hoffman; S Lipsitz; T Pisansky; J L Weese; L Solin; A B Benson
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  The value of imaging techniques in the staging of pancreatic cancer.

Authors:  J Kulig; T Popiela; A Zajac; S Kłek; P Kołodziejczyk
Journal:  Surg Endosc       Date:  2004-12-02       Impact factor: 4.584

6.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.

Authors:  D B Evans; T A Rich; D R Byrd; K R Cleary; J H Connelly; B Levin; C Charnsangavej; C J Fenoglio; F C Ames
Journal:  Arch Surg       Date:  1992-11

7.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

Authors:  Matthew H G Katz; Peter W T Pisters; Douglas B Evans; Charlotte C Sun; Jeffrey E Lee; Jason B Fleming; J Nicolas Vauthey; Eddie K Abdalla; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Rosa F Hwang
Journal:  J Am Coll Surg       Date:  2008-03-17       Impact factor: 6.113

8.  Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Authors:  Sohei Satoi; Hiroki Yamaue; Kentaro Kato; Shinichiro Takahashi; Seiko Hirono; Shin Takeda; Hidetoshi Eguchi; Masayuki Sho; Keita Wada; Hiroyuki Shinchi; A Hon Kwon; Satoshi Hirano; Taira Kinoshita; Akimasa Nakao; Hiroaki Nagano; Yoshiyuki Nakajima; Keiji Sano; Masaru Miyazaki; Tadahiro Takada
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-08       Impact factor: 7.027

9.  Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.

Authors:  Rebecca J McClaine; Andrew M Lowy; Jeffrey J Sussman; Nathan Schmulewitz; David L Grisell; Syed A Ahmad
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.